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Abstract
Fibrosis can occur in tissues in response to a variety of stimuli. Following tissue injury, cells undergo
transformation or activation from a quiescent to an activated state resulting in tissue remodelling.
The fibrogenic process creates a tissue environment that allows inflammatory and matrix-
producing cells to invade and proliferate. While this process is important for normal wound healing,
chronicity can lead to impaired tissue structure and function.
This review examines the major factors involved in transforming or activating tissues towards
fibrosis. The role of genetic variation within individuals affected by fibrosis has not been well
described and it is in this context that we have examined the mediators of remodelling, including
transforming growth factor-beta, T helper 2 cytokines and matrix metalloproteinases.
Finally we examine the role of Toll-like receptors in fibrosis. The inflammatory phenotype that
precedes fibrosis has been associated with Toll-like receptor activation. This is particularly
important when considering gastrointestinal and hepatic disease, where inappropriate Toll-like
receptor signalling, in response to the local microbe-rich environment, is thought to play an
important role.
Background
Fibrosis is a wound-healing response by which the body
attempts to repair itself following injury. Acute and, more
commonly, chronic injury from a wide variety of insults
leads to organ fibrosis. Organ systems have different cel-
lular and molecular mechanisms that result in fibrosis [1-
6]. Fibrous tissue contains extracellular matrix (ECM) but
in different ratios to normal tissue. In particular, there is a
significantly increased amount of type I collagen, with
progressive fibrosis eventually leading to a distortion of
the normal organ architecture [7,8]. The distorted archi-
tecture, along with loss of normal cellularity, leads to a
loss of function of the underlying organ. For example,
fibrosis in the liver can interfere with drug metabolism,
cause accumulation of toxic metabolites and lead to the
synthetic failure of important coagulation factors. In lung
tissue, fibrosis leads to poor blood-gas exchange resulting
in progressive hypoxia as the disease process advances.
There is also strong evidence linking fibrotic progression
and angiogenesis [9].
Fibrous tissue is laid down by cells with a mesenchymal-
like phenotype. In the liver the hepatic stellate cell (HSC)
is the major cell responsible for fibrosis, with activation of
HSC being a key fibrotic event, although fibroblasts and
bone marrow derived fibrocytes all contribute [10-13].
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Fibrosis has been described in virtually every organ and
most evidently in the liver. Other organs include the
lungs, skin, blood vessels, heart and kidneys. In the UK,
excessive alcohol consumption remains the most com-
mon cause of hepatic fibrosis. Worldwide chronic hepati-
tis B and C are the principle factors and are a major cause
of morbidity and mortality. At a molecular level, trans-
forming growth factor-beta (TGF-β), tissue inhibitor of
metalloproteinases (TIMP) and matrix metalloprotein-
ases (MMP) are the key factors involved in the develop-
ment of fibrogenesis [14,15]. There are a number of other
factors contributing to fibrogenesis that may play more
significant roles in particular organs. Reactive oxygen spe-
cies in lungs and liver [16-18], hypoxia inducible factor in
kidneys [4] and angiotensin II in blood vessels [19] are
examples. In this review we focus on TGF-β, IL-13, TIMP
and MMP, the major factors implicated in fibrogenesis.
The role of TGF-β in fibrogenesis
The elucidation of the pathways involved in TGF-β signal
transduction has provided new therapeutic targets for the
prevention or treatment of fibrosis. TGB-β is a pleio-
trophic growth factor which is involved in fibroblast
chemotaxis and proliferation. Transient TGB-β1 activity is
known to participate in the repair and regeneration of tis-
sues. However, persistent TGB-β1 function induces exces-
sive fibrosis and, ultimately, scarring of both skin and
internal organs [20]. TGB-β promotes production of sev-
eral ECM proteins, including type I collagen, by stimulat-
ing its gene transcription. It also influences MMP/TIMP
expression and T cell function and, thus, inflammatory
reactions are also influenced by TGF-β [21]. COL1A1 and
COL1A2 are the genes encoding the polypeptides which
form Type I collagen which is the most abundant product
of fibrosis, with the development of fibrosis correspond-
ing with an increased rate of the transcription of these two
genes [22-24]. Interestingly, enhancer sequences for
COL1A1 include binding sites for Smad, Sp1, p38 MAPK
and NF-1 [25]. The enhancer region for COL1A2 contains
corresponding regions for Smad, Sp1, AP-1 [26-29]. These
regulatory gene proteins are known to enhance the effects
of TGF-β  COL1A2  expression along with the cAMP
response element binding protein (CBP) and p300 coacti-
vators [30].
TGF-β is secreted in inactive form which is then activated
following proteolysis [21]. Once active, TGF-β is free to
bind to its receptors and the resulting signal transduction
pathway in the cytoplasm involves activation/transloca-
tion of Smad (a family of gene regulatory proteins) to the
nucleus (Figure 1). Smad 1, 2, 3, 5 and 8, also known as
receptor associated Smads (R-Smads), become phosphor-
ylated when the TGF-β and BMP receptors are activated.
Once phosphorylated, these R-Smads dissociate from the
receptor and must complex with Smad 4 before they can
translocate to the nucleus. Transcription of target genes is
then achieved when the phosphorylated Smad complex
binds to a specific area of DNA. A number of co-activators
(for example, CBP and p300) and transcription factors are
also involved in modulating sites of transcription [21].
Smad 6 and 7, unlike other members of the Smad family,
prevent phosphorylation and thus activation of these
Smad complexes are involved in TGF-β receptor degrada-
tion [31].
In addition to activation of the Smad signal transduction
pathway, TGF-β activates the mitogen activated protein
kinase (MAPK) family (Figure 1) [21]. The TGF-β response
is enhanced or inhibited depending on the particular
MAPK pathway involved. P38 MAPK and c-Jun N-termi-
nal kinase (JNK) can activate Smad 3 [32,33] and p38
MAPK also strengthens interaction between Smad3 and
coactivators [34]. Decreased Type I collagen expression
has generally been demonstrated with p38 MAPK inhibi-
tion [32,33,35]. The final MAPK pathways - extracellular
signal regulated kinase (ERK) - inhibit Smad signal trans-
duction, as well as BMP, and Smad1 effects on transcrip-
tion [36]. The impact of ERK on collagen gene
transcription is cell specific with ERK causing increased
collagen production in some cells and decreased produc-
tion in others [37].
IL-13 and fibrosis
The cytokine environment also plays a role in tissue
remodelling and it seems likely that they can influence the
phenotypic changes seen in different cell types in fibrotic
tissue. IL-13 is a Th2 cytokine that is known to induce
fibrosis through the regulation of TGF-β1 production and
activation [38,39]. IL-13 binds to two primary receptor
chains IL-13Ralpha1 and IL-13Ralpha2 (Figure 1). IL-
13Ralpha1 is expressed in healthy tissue and binds IL-13
through the formation of a heterodimer complex with IL-
4Ralpha chain. This complex formation culminates in sig-
nal transduction via the JAK/STAT6 pathway [40,41]. IL-
13Ralpha2, on the other hand, is only marginally
expressed in normal healthy tissue and over-expressed in
several abnormal cells including cancerous and fibrotic.
However, it can bind IL-13 with a high affinity with medi-
ation of signal transduction, thought to be STAT6 inde-
pendent, signalling instead through the AP-1 pathway
(Figure 1) [39]. Due to its lack of expression in normal tis-
sue and over expression in cancer cells and during fibrosis,
it has been suggested that IL-13Ralpha2 chain may serve
as a novel biomarker for diseased cells and a target for
receptor-directed therapeutics [39,42,43].
Fibroblast IL-13Ralpha2 expression has been reported in
several fibrotic diseases including idiopathic interstitial
pneumonia, schistosomiasis and non-alcoholic steato-
hepatitis [44-46]. Within the context of hepatic disease,Fibrogenesis & Tissue Repair 2009, 2:6 http://www.fibrogenesis.com/content/2/1/6
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IL-13Ralpha2 is expressed in activated HSCs but not qui-
escent HSCs, with expression strongly induced by both
TGF-β1 and also TNF-α [46]. Interestingly, TGF-β inde-
pendent IL-13 induced fibrosis has also been identified,
within the context of parasitic disease, with IL-13Ralpha2
over expression acting as a soluble decoy receptor and
ultimately decreasing fibrosis [47].
MMPs and TIMPs
MMPs and TIMPs are also responsible for maintaining
integrity of the ECM. There are many different types of
metalloproteinases, some of which are specific and others
that are less discriminating to ECM substrates. Their pres-
ence is required to degrade the wide variety of compo-
nents of the ECM. Excessive catabolism of ECM is kept in
check with several mechanisms, including the secretion of
TIMPs. TIMPs work by binding to MMPs thereby blocking
their activity.
Expression of MMP subtype is tissue dependent with dif-
ferences in amino acid sequence of MMPs seen amongst
animal species [48]. MMP-1 is significantly expressed by
several types of cells including the HSC. MMP-13 is the
rodent homologue of human MMP-1 [49-51]. Following
liver injury, elevated levels of MMP-1 and MMP-13 RNA
have found in human and rodent liver tissue respectively
[51-54]. Elevated metalloproteinase expression, in acute
liver injury has been shown to occur for only a short
period post insult [54] and, in chronic liver injury, is lim-
ited to the period of fibrogenesis [55]. After liver injury,
HSCs become activated and express MMP-2 and MMP-14
[50,56]. Elevated MMP-2 and MMP-14 levels have been
demonstrated in fibrotic and cirrhotic liver tissue, with the
exception of HCV induced cirrhosis [57,58]. MMP-2 pro-
motes proliferation and migration of the hepatic stellate
cells and its activation is dependent on MMP-14 [59].
Both TIMP-1 and TIMP-2 can inhibit MMP 2.
There is brief expression of MMP-3 following HSC activa-
tion and acute toxic liver injury. The most important role
MMP-3 is known to play in fibrosis is through cleavage of
MMP precursors such as MMP-1, -3, -7, -8, -9 and -13 to
their active forms [60-65]. However, there is contradictory
evidence in the literature on whether MMP-3 expression is
increased or decreased in chronic liver injury [66-68].
Similarly, variable results have been obtained for MMP-9
expression in both acute and chronic liver injury [57,69-
71]. IL-13 is a potent inducer of MMP-9. The role of MMP-
9 in fibrogenesis is thought to primarily involve activation
of TGF-β [72]. This is significant as initial collagen pro-
duction by the HSC is stimulated by TGF-β [73].
TIMP-1 and TIMP-2 are the main TIMPs associated with
fibrosis. In the liver, these TIMPs are primarily produced
by HSCs, although other cells also contribute to TIMP
production [74]. In hepatitis C infection, the degree of
hepatic fibrosis is correlated with the level of TIMP-1
mRNA and protein [53]. In addition to binding, and
thereby inhibiting matrix metalloproteinases, TIMP-1 also
prevents apoptosis of HSCs [75,76]. Elevated levels of
TIMP-2 in serum and liver mRNA are found in human
hepatitis C virus (HCV) liver disease. However, fibrosis
does not have to be present for raised TIMP-2 levels to be
detectable in HCV patients [77,78]. In rodents, TIMP-2
mRNA reaches its highest levels in acute toxicity within 3
days, whereas it is not increased with chronic toxic liver
injury [57,70,79].
Host genetic factors and fibrosis
Before discussing the role of host genetic factors in fibro-
sis, it is essential to establish some basic principles of
genetic epidemiology and the limitations of studying
genetic polymorphisms in the context of complex multi-
factorial human diseases [80]. The overwhelming major-
Interleukin (IL)-13/transforming growth factor (TGF)-β sig- nalling pathways Figure 1
Interleukin (IL)-13/transforming growth factor 
(TGF)-β signalling pathways. IL-13 signalling via IL-4Rα/
IL-13Rα1 occurs via the JAK/STAT6 pathway and can cause 
increased collagen production from fibroblasts, recruit 
immune effector cells and enhance chemokine expression. 
Signalling via IL-13Rα2 in macrophages activates AP-1 induc-
ing TGF-β secretion. Similarly IL-13Rα2 expression can be 
enhanced by TGF-β in hepatic stellate cells. TGF- β activates 
two serine/threonine kinase receptors and signals through 
Smad phosphorylation. TGF-β can also activate mitogen acti-
vated protein kinase signalling.Fibrogenesis & Tissue Repair 2009, 2:6 http://www.fibrogenesis.com/content/2/1/6
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ity of polymorphisms studied are single nucleotide
polymorphisms (SNPs) that occur with a frequency of
>1% in the normal population (in contrast to 'mutations'
that occur with a frequency of <1%). It is estimated that
the human genome contains up to 10 million SNPs,
although not all have thus far been identified. Most SNPs
are located within non-coding regions of the genome.
However, of those that are located within coding
sequence, most are non-synonymous and are not associ-
ated with the alteration of the amino acid sequence ren-
dering them of no functional consequence. Other types of
genetic variation include deletion and insertion polymor-
phisms and microsatellite repeat polymorphisms.
There has been an exponential rise in the number of pub-
lished genetic association studies. Quite often, a report of
a single genetic marker is published with great promise,
only to be followed by several negative studies that fail to
reproduce the original observation. There is no doubt that
the strategy of genetic association studies could be a pow-
erful tool for dissecting human diseases, provided certain
principles are observed in order to minimize the chances
of false positive, and negative, reports. The most impor-
tant of these principles include: rigorous definition of dis-
ease phenotype; choice of candidate genes that are
plausibly linked to the pathophysiology of the disease
under study; selection of polymorphisms with known (or
at least potentially) functional consequences; choice of
genetic markers that are reasonably frequent in the popu-
lation under study (variant allele frequency of at least
5%); appropriate selection of controls that are matched
for ethnicity, age, gender and environmental exposures;
and design of studies that are adequately powered to pro-
duce a valid result. Even then, the statistical analyses of
such studies have to take into account the real problem of
false positive results by using multiple testing. Appropri-
ate corrections for multiple testing have to be applied or,
alternatively, the positive findings should be regarded as
preliminary and should be validated in an independent
set of cases and controls. Finally, the genetic epidemiol-
ogy has to involve basic science in order to unravel and
validate the molecular mechanisms involved. Adherence
to these basic principles will ensure that false positive
trails are minimized and will offer a true opportunity to
understand the complex multifactorial human diseases.
There has never been a better time to stress the necessity
for an adherence to these principles, as the advancement
in genotyping technology has made possible the annota-
tion of the entire human genome. Current technology
allows us to genotype up to 500,000 SNPs in one run. We
have witnessed a shift towards these so-called whole
genome association studies, where large multi-centre con-
sortia attempt to examine a very large number of cases and
controls for a particular disease. The power of these stud-
ies allows for an exploratory phase where thousands of
SNPs are examined and a validation phase that attempts
to replicate positive associations independently.
Having set the background to the study of genetic poly-
morphisms, we can now examine the role of these in the
context of fibrosis. Pathogenic fibrosis typically results
from chronic inflammatory reactions, many of which will
be triggered by an infectious agent or a chemical assault
which drives the chronic inflammation and the subse-
quent development of fibrosis. The role of polymor-
phisms in several cytokine genes has been examined in
the context of fibrotic disease, often with conflicting
results. We will concentrate on genetic markers that have
relevance to pathogenesis of fibrotic diseases and will
only consider markers that satisfy the criteria listed above.
Perhaps the most relevant gene in the context of fibrosis is
TGF-β. Several SNPs have been identified in this gene and
some are associated with elevated TGF-β1 concentrations
in human plasma [81-83]. However, only SNPs within the
coding region of TGF-β1 (Leu10Pro and Arg25Pro) have
been shown to be associated with increased fibrotic risk
[84-88] (Table 1). Gewaltig et al. reported that the carriage
of at least one Pro at codons 10 and/or 25 was signifi-
cantly associated with a faster progression of hepatic
fibrosis following chronic hepatitis C infection. The fibro-
sis progression rate of patients with genotypes 10LeuPro
and 10ProPro was almost three times as fast as those hav-
ing genotype 10LeuLeu. Stage and histological activity
grade of fibrosis in 25ArgPro in comparison to 25ArgArg
were also higher [84]. Tag et al. were able to reproduce
similar findings reporting an increased risk of higher
grades of fibrosis in carriers of the 25ArgPro genotype [85].
However, these were small studies and findings from
other groups have either failed to replicate the associa-
tions or reported opposite associations. For example,
Powell et al. showed that the 25ArgArg genotype was asso-
ciated with increased risk of hepatic fibrosis following
HCV infection [87]. The same polymorphisms have been
addressed in other hepatic disorders. Österreicher et al.
studied the role of host genetic factors in the progression
of hereditary haemochromatosis and showed that the
25ArgPro genotype increased the risk of cirrhosis by nearly
threefold compared to 25ArgArg genotype [86]. The direc-
tion of association is similar to that reported by Gewaltig
and Tag et al. but the studies remain small and require
definitive validation in larger case control studies.
TGF-β1 production is also known to be enhanced by angi-
otensin II, the principal effector molecule of the renin-
angiotensin system. A statistically significant relationship
was also seen between the polymorphism in the promoter
region of the angiotensinogen gene (AT-6) and the stage
of hepatic fibrosis [87]. Individuals with the adenine/ade-
nine homozygous genotype were more likely to haveFibrogenesis & Tissue Repair 2009, 2:6 http://www.fibrogenesis.com/content/2/1/6
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increased hepatic fibrosis compared with individuals
inheriting the adenine/guanine or the guanine/guanine
homozygous genotype (Table 1).
The  TNF-A-308 G > A polymorphism is known to be
involved in a number of inflammatory conditions. Car-
riage of the pro-inflammatory A allele has been shown to
increase the odds ratio for severe disease in both hepatic
fibrosis and also fibrosing alveolitis (Table 1). Yee et al.
reported carriage of the -308A allele was associated with a
fivefold increased risk of cirrhosis following HCV infec-
tion [89]. These findings were reported by Kusumoto et
al., with carriage of 'A' at TNF-α -238 or -308 correlating
with significantly higher serum levels of Type IV collagen
7S, which is a marker for advanced hepatic fibrosis [90].
However, other reports failed to confirm these associa-
tions. Carriage of TNF-A-308 A has also been assessed
within the context of fibrosing alveolitis in several small
studies. Whyte et al. assessed the frequency of the poly-
morphism in two independent case-control studies, one
English and one Italian, and showed a significant associa-
tion of TNF-A-308 A carriage with increased risk of fibro-
sing alveolitis in the Italian, but not the English, study
[91]. Studies by Pantelidis et al. and Riha et al. confirmed
this association but the findings require confirmation in a
much larger study with appropriately matched controls
[92,93].
Other cytokine genes in which genetic variation has been
examined within the context of fibrotic disease include
interleukin-10, interferon-gamma and the interleukin
(IL)-1 receptor antagonist. IL-10 is an anti-inflammatory
Th2 cytokine that down regulates IL-1β, TNF-α, inter-
feron-γ and other pro-inflammatory cytokines and has a
modulatory effect on hepatic fibrogenesis. IL-10 levels dif-
fer widely between individuals, possibly because of poly-
morphisms in the promoter region of the IL-10 gene at
positions -592, -819 and -1082 [94,95]. Promoter poly-
morphisms have been associated with several inflamma-
tory conditions including hepatitis B virus-induced
hepatocellular carcinoma and other cancers [96,97]. We
have previously reported that homozygosity for the low-
IL-10 ATA haplotype increased the risk of non-cardia gas-
tric cancer [98]. IL-10 SNPs have been studied in the con-
text of hepatic fibrosis. An early study by Powell et al. did
not show a correlation between stages of HCV induced
fibrosis and IL-10 promoter polymorphisms [87]. How-
ever, a study published the same year, looking at their role
in alcoholic liver disease induced fibrosis, indicated a
strong association between possession of the A allele at
position -592 in the IL-10 promoter region and fibrosis
[99]. It was subsequently suggested that defining disease
progression would possibly be more appropriate based on
the speed of fibrotic development (that is, fast versus
slow). A subsequent study by Knapp et al. looking at HCV-
induced fibrosis, showed a higher frequency of the low IL-
10 producing haplotypes (ACC/ACC and ATA/ATA) in
patients termed 'fast fibrosers' [100] (Table 1).
Polymorphisms in interleukin-1 that have been assessed
in the context of fibrotic disease are mainly related to the
IL-1 receptor antagonist. Whyte and colleagues looked at
the IL-1RN polymorphism at C+2018T in two European
cohort studies of pulmonary fibrosis along with the previ-
ously mentioned TNF-A-308 G > A polymorphism [91].
As with the TNF-A-308 G > A polymorphism, carriage of
the rarer T allele at IL-1RN +2018 was associated with an
increased risk of fibrosing alveolitis in the Italian but not
the English cohort. This is again possibly due to small
study numbers. A variable tandem repeat genetic variant
in intron 2 of IL-1RN which is in strong linkage disequi-
librium with the C+2018T has also been studied. How-
ever, no association has been defined in either hepatic or
pulmonary fibrosis [93,101,102]. Carriers of interfernon
(IFN)-G +874 T allele have also been shown to have a sig-
nificantly higher rate of liver cirrhosis and early recurrent
hepatitis C after transplantation [103,104]. The AA geno-
type is associated with the low levels of IFN-gamma pro-
duction which is thought to inhibit the appropriate level
of T-helper (Th1) response needed to combat HCV viral
load and subsequent disease progression [105,106].
Assessment of genetic variation in chemokine receptors
has also been studied in the context of HCV-induced
hepatic fibrosis. Hellier et al. reported a significant associ-
ation between severe HCV-induced hepatic fibrosis and
carriage of both CCR5 Δ32 and the K variant of the MCP-
2 Q46K polymorphism [107]. In total 20 polymorphisms
in seven CC chemokines and their receptors were assessed
in the study which comprised 672 patients. Both chemok-
ines are involved in T cell recruitment/migration and
processes relevant to HCV clearance or persistence. Partic-
ularly in relation to CCR5 Δ32, for which functional data
is available, carriage of the 32 bp deletion results in a non-
functional protein which will impact on viral persistence
[108]. The -2518 MCP-1 promoter polymorphism has
also been shown to be a risk factor for HCV induced
hepatic fibrosis. An elegant study by Muhlbauer et al.
showed that carriage of MCP-1 -2518 G allele, which is
associated with increased MCP-1 levels, was associated
with more advanced fibrosis and severe inflammation
[109]. The study also demonstrated, for the first time, an
association of the MCP-1 polymorphism with MCP-1 tis-
sue levels.
Polymorphisms involved in other cellular processes
important in hepatic fibrotic development have also been
studied. Mutations within the haemochromatosis (HFE)
gene involved in iron storage and accumulation have
been shown to be associated with higher grades of inflam-Fibrogenesis & Tissue Repair 2009, 2:6 http://www.fibrogenesis.com/content/2/1/6
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mation and more severe hepatic fibrosis, although these
findings were not replicated in other published studies
[110,111]. Potential explanations for the lack of valida-
tion include: small sample size; different histological
scores for hepatic fibrosis; ethnicity; population stratifica-
tion; and uncontrolled variables associated with disease
progression. A promoter polymorphism within the mye-
loperoxidase gene which is involved in activation of HSCs
and the production of ECM-MPO G-463A has also been
shown to be associated with advanced fibrosis when the
variant A allele was present [112]. Polymorphisms in
genes involved in lipid transportation have also been
Table 1: Genetic polymorphisms with relevance to fibrosis risk.
Gene Known variation Effect Reference
TGF beta Leu10Pro LeuLeu showed a slow progression of fibrosis
Carriage of Pro associated with faster fibrotic 
progression
[84-88]
Arg25Pro Carriage of Pro associated with faster fibrotic 
progression
Angiotensin G-6A Carriage of AA genotype associated with increased risk 
of fibrosis
[87]
TNF-alpha G-308A A allele associated with hepatic fibrosis, hepatic cancer, 
fibrosing alveolitis
[91,93,136,137]
IL-10 C-592A/-819/G-1082A Carriage of ATA associated with ALD and HCV induced 
fibrosis
[99,100,138]
IL-1 IL-1RNC +2018T T allele associated with increased risk of fibrosing 
alveolitis
[91]
IFN-gamma T+874A T allele associated with higher rate of liver cirrhosis 
following Hep C infection
[103,104]
CC chemokine receptor 5 (CCR5) insertion/deletion (Δ32) Carriage of Δ32 associated with severe fibrosis [107]
MCP-2 Q46K Carriage of the K variant is associated with more severe 
fibrosis
[107]
MCP-1 G-2518A Carriage of G allele associated with increased risk of 
hepatic inflammation and fibrosis
[109]
Haemochromatosis gene (HFE)G + 8 4 5 A
C+187G
Heterozygous genotypes associated with increased 
inflammation and fibrosis
[110,111]
Myeloperoxidase
(MPO)
G-463A Minor allele associated with increased risk of advanced 
fibrosis in CHC patients
[112]
low density lipoprotein receptor (LDLR) G+1170A Carriage of G associated with increased risk of fibrosis [113]
Apolipoprotein E (Apo E) E4 allele Carriage of E4 allele associated with protection against 
HCV induced liver damage
[114]
DDX5 DEAD box polypeptide 5 and 
POLG2 SNPs
Minor allele associated with increased risk of advanced 
fibrosis in CHC patients
[139]
CD14 C-159T T allele associated with higher levels of acute phase 
proteins and advanced ALD
[140]
TLR4 D299G
T399I
Both variant allele confer protection against fibrosis [141,142]
CHC, chronic hepatitis cancer; ALC, alcoholic liver cirrhosis; ALD, alcoholic liver disease; HCV, hepatitis C virusFibrogenesis & Tissue Repair 2009, 2:6 http://www.fibrogenesis.com/content/2/1/6
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assessed within the context of HCV-induced liver fibrosis.
These pathways are thought to promote viral endocytosis.
Carriage of the G allele of the low density lipoprotein
receptor polymorphism - G+1170A - has been shown to
render patients more susceptible to developing severe
HCV-induced fibrosis [113]. Conversely, carriage of the
apolipoprotein (apoE) E4 allele has been shown to pro-
tect against severe liver damage induced by HCV [114]
(Table 1).
Toll-like receptors (TLRs) and fibrosis
There is growing interest in the role of the innate immune
system, especially TLRs, as regulators of wound healing
and especially fibrosis. TLRs are a highly conserved family
of germline-encoded receptors that recognize structural
motifs expressed by bacteria, viruses and fungi. Stimula-
tion of TLRs by these ligands activates numerous signal-
ling cascades which ultimately culminate in
proinflammatory cytokine production and other immune
responses, including cell survival and apoptosis [115].
Currently 10 human TLRs have been identified, each with
different ligand specificity. TLR4 is known as the lipopol-
ysaccharide (LPS) receptor, due to the original reports
which demonstrated the relationship between TLR4 and
LPS recognition [116,117]. LPS - or endotoxin - a compo-
nent of the Gram-negative bacterium outer membrane is
are now known to be one of a collection of ligands that is
recognized by TLR4. However, it is known that TLR4 (and
possibly other TLRs) can detect other exogenous as well as
endogenous ligands, many of which are most abundant
during tissue injury such as hyaluronan, fibronectin S100
proteins and heat shock proteins 60 and 70 [118]. Along
with TLR4, TLRs 1, 2, 5, 6 and 9 are involved in bacterial
recognition. TLR 1, 2 and 6 recognize lipoprotein from
Gram-positive bacteria and TLR5 is involved in bacterial
flagellin sensing. TLR9 recognizes non-methylated CpG-
containing DNA from bacteria. In contrast, TLR 3, 7, 8 and
9 recognize viral nucleic acids. TLRs although similar in
their structure with a leucine-rich repeat domain and a
Toll/IL-1 receptor (TIR) domain are separated on the basis
of their cellular location with TLR 1, 2, 4, 5 and 6 located
on the cell surface, whilst the others are associated with
endosomal/lysosomal compartments where the possibil-
ity of encountering host DNA and therefore eliciting self-
recognition is reduced [119].
Following ligand binding, TLR signalling cascades are ini-
tiated from the TIR domain and many of the signalling
molecules that mediate the intracellular response are
common between the TLRs [120]. TLR signalling has been
divided into MyD88-dependent and MyD88-independent
(TRIF dependent) pathways (Figure 2). MyD88-depend-
ent signalling culminates in activation of the transcription
factors NF-kB and AP-1 (via downstream MAPK path-
ways) and the production of numerous pro-inflammatory
cytokines and immune mediators. These transcription fac-
tors are also activated via MyD88-independent signalling
but their activation is slightly delayed [121]. All TLRs with
the exception of TLR3 signal via the MyD88-dependent
signalling pathway. MyD88-independent signalling is
involved in the induction of interferon-inducible genes
including IRF3 which are important for anti-viral and
anti-bacterial responses [122,123]. TLR4 is the only TLR
known to utilize both the MyD88-dependent and inde-
pendent pathways [124,125].
Although all immune cells express TLRs, these receptors
are also present on other classes of cell. Nevertheless, the
ability of different cell types to recognize and respond to
microbial ligands differs. Generally, TLR expression on
immune cells is there as the archetypical response to infec-
tion. TLR activation on other cell types, including epithe-
lial cells, whilst contributing to the immune response has
also been suggested to lead to tissue scarring and fibrosis
[126,127].
Impaired TLR4 and nine responses through defective sig-
nalling, and also the presence of genetic variations, have
been shown to reduce hepatic fibrosis [128-130]. A
number of in vivo observations also support a role for TLRs
in promoting fibrogenesis, although this has only been
studied within the context of hepatic disease. It has also
been shown that the intestinal microbiota is at least in
part responsible for activating TLR4 containing cells
within the liver, especially quiescent HSCs ultimately
evoking hepatic fibrogenesis through modulation of TGF-
β signalling [128,131-133]. TLR induced activation of p38
MAPK and JNK has also been shown to be involved in
increased production of collagen by HSCs [134]. The link
between the intestinal microbiota and hepatic TLR activa-
tion is through the portal vein. The most likely explana-
tion is that damage incurred to the portal system, during
chronic hepatic injury, affects the intestinal barrier func-
tion allowing increased bacterial translocation [128,129]
(Figure 2). This view is supported by studies using gut-
sterilized mice that have shown a strong reduction in
fibrogenesis compared to conventional mice [135].
Conclusion
Fibrosis can occur in almost any tissue type, with analysis
of the cellular and molecular mechanisms showing simi-
larities irrespective of location. Trauma/insult usually
through exogenous stimuli, chemical or microbiological,
results in innate immune cell activation which triggers a
chronic inflammatory response that is central to fibrotic
perpetuation. TGF-β plays a pivotal role in the fibrotic
development through its influence on MMP/TIMP expres-
sion, T cell function and also ECM production. However,Fibrogenesis & Tissue Repair 2009, 2:6 http://www.fibrogenesis.com/content/2/1/6
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further studies are required in order to fully understand
the complex relationship. The situation is further compli-
cated by the contribution of host genetic polymorphisms
to an individual's risk.
Chronic inflammation, whether caused by microbes,
chemical or physical trauma favours fibrotic progression.
A series of intricate host responses are initiated that, on
one hand, are attempting to initiate repair of the tissue
damage through resolution of the inflammation, whilst
also trying to eliminate the infection. The Th2-type
cytokine response (typified by IL-13) seen in fibrosis is
pivotal to this as is the increasing understanding of TLR
signalling and the impact of genetic polymorphisms on
these systems. Therapies aimed at suppressing TLR4 sig-
nalling, either through preventing LPS release or TLR4
inhibition, is already being considered in the context of
hepatic fibrosis, although other fibrotic targets are also
under investigation. Understanding the interplay between
trauma stimuli and tissue repair is fundamental to resolv-
ing the complex interplay between the causes of chronic
inflammation and the host's genetic disposition to
fibrotic progression, which will aid the development of
new and more effective anti-fibrotic strategies in the
future.
Signalling pathways triggered by TLR4 activation as a result of damage to the portal system Figure 2
Signalling pathways triggered by TLR4 activation as a result of damage to the portal system. Altered barrier func-
tion resulting in increased bacterial translocation allows bacterial products including lipopolysaccharide (LPS) to activate 
hepatic stellate cells (HSCs) through Toll-like receptors (TLRs) (TLR4 shown as an example TLR). Activation of TLR4 through 
LPS binding initiates numerous signalling cascades which culminate in activation of transcription factors NF-κB and AP-1 and 
production of inflammatory cytokines/chemokines and immune mediators. This activation sensitises HSCs to the effects of 
transforming growth factor TGF-β which ultimately results in HSC activation and increased extracellular matrix/collagen pro-
duction resulting in increased hepatic fibrosis.Fibrogenesis & Tissue Repair 2009, 2:6 http://www.fibrogenesis.com/content/2/1/6
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